19:33 , Jun 16, 2017 |  BC Extra  |  Financial News

Actelion spinout Idorsia rises in first trading day

Idorsia Ltd. (SIX:IDIA) gained CHF3.65 (37%) to CHF13.65 in its first day of trading on Friday. The closing price valued the company at CHF1.5 billion ($1.5 billion). Idorsia was spun out of Actelion Ltd. (SIX:ATLN),...
23:39 , Jun 9, 2017 |  BC Extra  |  Financial News

Actelion spinout Idorsia to list next week

On June 16, shares of Idorsia Ltd. (Allschwil, Switzerland) are to begin trading on the SIX Swiss Exchange. Idorsia will house the drug discovery and early clinical pipeline businesses of Actelion Ltd. (SIX:ATLN), which Johnson...
19:49 , May 26, 2017 |  BC Week In Review  |  Clinical News

Actelion reports Phase II data for cenerimod in SLE

Actelion Ltd. (SIX:ATLN) reported data from a double-blind, placebo-controlled Phase II trial in 67 patients with systemic lupus erythematosus (SLE) showing that cenerimod dose-dependently reduced lymphocyte count. Cenerimod was well tolerated. Patients received placebo or...
20:39 , May 22, 2017 |  BC Extra  |  Clinical News

Actelion reports hypertension data amid Idorsia spinout

In a pipeline update outlining candidates it plans to spin out into newco Idorsia Ltd. , Actelion Ltd. (SIX:ATLN) said ACT-132577 led to "statistically significant dose-dependent" reductions in both diastolic and systolic blood pressure in...
03:07 , Feb 4, 2017 |  BioCentury  |  Strategy

Actelion, take two

After surviving takeover attempts, an investor mutiny and a make-or-break gamble on Opsumit macitentan, Actelion Ltd. co-founder and CEO Jean-Paul Clozel finally took a deal management couldn’t refuse. Johnson & Johnson ’s proposed $30 billion...